歡迎來到上海谷研實(shí)業(yè)有限公司網(wǎng)站！
咨詢電話：18321818584歡迎來到上海谷研實(shí)業(yè)有限公司網(wǎng)站！咨詢電話：18321818584
簡(jiǎn)要描述：泛素特異性蛋白酶OTB1抗體免 疫 原；KLH conjugated synthetic peptide derived from human OTUB1: 51-150/271
產(chǎn)品型號(hào)：GOY-01K0563廠商性質(zhì)：科研更新時(shí)間：2023-10-24 00:00:00訪 問 量：157產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
泛素特異性蛋白酶OTB1抗體
產(chǎn)品名稱 | 英文名稱 | 貨號(hào) |
泛素特異性蛋白酶OTB1抗體 | OTUB1 | GOY-01K0563 |
商品屬性：
英文名稱: OTUB1
中文名:泛素特異性蛋白酶OTB1抗體
別 名；Deubiquitinating
enzyme OTUB1; hOTU1; OTB1; OTU domain containing ubiquitin aldehyde binding
protein 1; OTU domain-containing ubiquitin aldehyde-binding protein 1; OTU1;
Otub1; OTUB1_HUMAN; Otubain 1; Otubain-1; Ubiquitin specific processing
protease OTUB1; Ubiquitin thioesterase OTUB1; Ubiquitin-specific-processing
protease OTUB1.
研究領(lǐng)域；細(xì)胞生物 免疫學(xué) 表觀遺傳學(xué)
抗體來源；Rabbit
克隆類型；Polyclonal
交叉反應(yīng)；(predicted:
Human, Mouse, Rat, Dog, Cow, Horse, Sheep, )
產(chǎn)品應(yīng)用；WB=1:500-2000
ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復(fù)）
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量；31kDa
細(xì)胞定位；細(xì)胞漿
性 狀；Liquid
濃 度；1mg/ml
免 疫 原；KLH
conjugated synthetic peptide derived from human OTUB1: 51-150/271
亞 型；IgG
純化方法；affinity
purified by Protein A
緩 沖 液；0.01M
TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
注意事項(xiàng)；This
product as supplied is intended for research use only, not for use in human,
therapeutic or diagnostic applications.
產(chǎn)品介紹:
OTUB1 is a 271 amino acid protein that contains
one OTU (ovarian tumor) domain and belongs to the OTU family of predicted
cysteine proteases. Expressed as two isoforms (one of which is present
throughout the body and the other of which is present only in lymphoid
tissues), OTUB1 functions as a hydrolase that can remove ubiquitin residues
from target proteins, thereby preventing protein degradation and playing an
important role in protein turnover. OTUB1 interacts with GRAIL and, via this
interaction, plays a role in the regulation and the induction of T-cell
anergy, a phenomenon that occurs when T-cells are rendered unresponsive to
their cognate antigens. Due to its interaction with GRAIL, OTUB1 is an
important regulator of immune responses in secondary lymphoid organs. Hydrolase that can specifically remove
'Lys-48'-linked conjugated ubiquitin from proteins and plays an important
regulatory role at the level of protein turnover by preventing degradation.
Regulator of T-cell anergy, a phenomenon that occurs when T-cells are
rendered unresponsive to antigen rechallenge and no longer respond to their
cognate antigen. Acts via its interaction with RNF128/GRAIL, a crucial
inductor of CD4 T-cell anergy. Isoform 1 destabilizes RNF128, leading to
prevent anergy. In contrast, isoform 2 stabilizes RNF128 and promotes anergy.
Surprisingly, it regulates RNF128-mediated ubiquitination, but does not
deubiquitinate polyubiquitinated RNF128. Deubiquitinates estrogen receptor
alpha (ESR1). Mediates deubiquitination of 'Lys-48'-linked polyubiquitin
chains, but not 'Lys-63'-linked polyubiquitin chains. Not able to cleave
di-ubiquitin. Also capable of removing NEDD8 from NEDD8 conjugates, but with
a much lower preference compared to 'Lys-48'-linked ubiquitin. Plays a key non-catalytic role in DNA repair
regulation by inhibiting activity of RNF168, an E3 ubiquitin-protein ligase
that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA
damage sites. Inhibits RNF168 independently of ubiquitin thioesterase
activity by binding and inhibiting UBE2N/UBC13, the E2 partner of RNF168,
thereby limiting spreading of 'Lys-63'-linked histone H2A and H2AX marks.
Inhibition occurs by binding to free ubiquitin: free ubiquitin acts as an
allosteric regulator that increases affinity for UBE2N/UBC13 and disrupts
interaction with UBE2V1. The OTUB1-UBE2N/UBC13-free ubiquitin complex adopts
a configuration that mimics a cleaved 'Lys48'-linked di-ubiquitin chain. |
多克隆抗體制備：
我公司合成抗原，保證陽性血清和抗體ELISA效價(jià)達(dá)到1：32000，由蛋白抗原制備的多抗，保證WB檢測(cè)結(jié)果是陽性。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià)，按節(jié)點(diǎn)收費(fèi)，為客戶節(jié)約成本。
鼠單克隆抗體制備:
客戶可根據(jù)項(xiàng)目實(shí)際需求情況靈活選擇進(jìn)行，我公司將為您的項(xiàng)目提供專業(yè)的建議。在制備過程中，與客戶互動(dòng)驗(yàn)證，確保最終制備的抗體ELISA陽性血清檢測(cè)達(dá)到合同要求的同時(shí)，也能滿足客戶抗體最終應(yīng)用驗(yàn)證需求。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià)，按節(jié)點(diǎn)收費(fèi)，為客戶節(jié)約成本。
重組抗體表達(dá)服務(wù):
重組抗體技術(shù)使制備人源化抗體和人源抗體成為可能，而這是其他常規(guī)的多克隆或單克隆抗體制備方法無法做到的。我公司已搭建好的抗體測(cè)序、重組抗體表達(dá)等先進(jìn)平臺(tái)，能為客戶提供各種類型的重組抗體表達(dá)服務(wù)，包含鼠源單克隆抗體構(gòu)建及表達(dá)、更換恒定區(qū)亞型的嵌合抗體表達(dá)，抗體人源化改造及表達(dá)等服務(wù)。
單項(xiàng)免疫學(xué)及檢測(cè)服務(wù):
我公司也為客戶提供單項(xiàng)免疫學(xué)和檢測(cè)服務(wù)，如動(dòng)物免疫、動(dòng)物飼養(yǎng)、抗體修飾服務(wù)（如FITC，HRP等的標(biāo)記）、以及ELISA，WB，IHC，DB等檢測(cè)服務(wù)。
抗體定制服務(wù):
已注冊(cè)商標(biāo)，主要用于抗體藥物發(fā)現(xiàn)和開發(fā)，是我公司針對(duì)有特定應(yīng)用要求和各種模型測(cè)試的客戶量身定制的專業(yè)服務(wù)，主要面向工業(yè)客戶。
產(chǎn)品咨詢
聯(lián)系人：銷售部
地址：上海市嘉定區(qū)澄瀏公路52號(hào)盛創(chuàng)企業(yè)
郵箱：[email protected]
手機(jī)：18321818584 / 15026555973歡迎您關(guān)注我們的微信了解更多信息
掃一掃電話
微信掃一掃